A novel serum signature with seven autoantibody candidates, including microtubule‐associated protein tau (MAPT), DnaJ homolog subfamily C member 8, lysine‐specific demethylase 4D, small EDRK‐rich factor 1A, cyclin‐dependent kinase inhibitor 1, advanced glycosylation end product‐specific receptor, and polycomb group protein ASXL1, could identify AD cases from controls with high accuracy (AUC = 0.94) in four cohorts.100. Here, MAPT is linked to Alzheimer disease.